After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
Morgan Stanley flagged upside risks if pipeline data impresses, Dupixent intellectual property proves more durable, or Eylea HD adoption accelerates. Downside risks include trial setbacks, competitive ...
Sanofi is scheduled to report results for the third quarter on Friday. Here is what you need to know. SALES FORECAST: The French drugmaker is expected to post sales of 12.23 billion euros ($14.20 ...
Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that is light on capital yet still heavy on scientific innovation. The cash ...
LONDON, Sept 4 (Reuters) - Shares in French drugmaker Sanofi (SASY.PA), opens new tab fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanofi ("Sanofi" or "the Company") (NASDAQ: SNY) for violations ...
Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the firm ...
On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, and sharply reduced the stock’s price target to $662 from $943.
Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite challenges, including the delayed regulatory submissions of Itepekimab. The delay in Itepekimab’s approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback